The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
Open accessPublished version of a preprint
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the rapidly unfolding coronavirus disease 2019 (COVID-19) pandemic 1,2. Clinical manifestations of COVID-19 vary, ranging from asymptomatic infection to respiratory failure. The mechanisms that determine such variable outcomes remain unresolved. Here we investigated CD4+ T cells that are reactive against the spike glycoprotein of SARS-CoV-2 in the peripheral blood of patients with COVID-19 and SARS-CoV-2-unexposed healthy donors. We detected spike-reactive CD4+ T cells not only in 83% of patients with COVID-19 but also in 35% of healthy donors. Spike-reactive CD4+ T cells in healthy donors were primarily active against C-terminal epitopes in the spike protein, which show a higher homology to spike glycoproteins of human endemic coronaviruses, compared with N-terminal epitopes. Spike-protein-reactive T cell lines generated from SARS-CoV-2-naive healthy donors responded similarly to the C-terminal region of the spike proteins of the human endemic coronaviruses 229E and OC43, as well as that of SARS-CoV-2. This results indicate that spike-protein cross-reactive T cells are present, which were probably generated during previous encounters with endemic coronaviruses. The effect of pre-existing SARS-CoV-2 cross-reactive T cells on clinical outcomes remains to be determined in larger cohorts. However, the presence of spike-protein cross-reactive T cells in a considerable fraction of the general population may affect the dynamics of the current pandemic, and has important implications for the design and analysis of upcoming trials investigating COVID-19 vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This cross-reactivity largely originates from previous exposure to circulating common cold coronaviruses [110-116].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [114]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“lymphocytes from 20% to 50% of unexposed donors display significant reactivity to SARS-CoV-2 Ag peptide pools (Figure 6).”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [114]
In the citing paper
“the T cell responses against SARS-CoV-2 are highly multi-antigenic and multi-specific, with tens of different epitopes recognized by CD4+ and CD8+ T cells in a given individual.”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [52]
In the citing paper
“The dominant cytokine produced by SARS-CoV-2-specific CD4+ T cells from COVID-19 patients is IFNγ (Braun et al., 2020; Grifoni et al., 2020; Rydyznski Moderbacher et al., 2020; Weiskopf et al., 2020), with a clear IFNγ, tumor necrosis factor (TNF), IL-2 protein signature of canonical Th1 cells (Braun et al., 2020; Rydyznski Moderbacher et al., 2020; Peng et al., 2020; Sekine et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“In contrast, the strikingly extended absence of SARS-CoV-2-specific CD4+ T cells was associated with severe or fatal COVID-19 (>day 22 PSO in some cases) (Braun et al., 2020; Rydyznski Moderbacher et al., 2020; Tan et al., 2020a).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“In contrast, substantial cross-reactive T cell memory has been reported, measurable in ∼28%–50% of people, depending on the study (Le Bert et al., 2020; Braun et al., 2020; Grifoni et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“SARS-CoV-2 infection elicits a Th1 CD4+ T cell response, with IFNγ and IL-2 being the primary cytokines produced by these cells and some TNFα production as well112,126-129.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
In the citing paper
“Specifically, when compared to those with mild COVID-19, patients with severe disease generated a weaker T cell response to the N-terminal portion of the SARS-CoV-2 S protein, a region that includes the critical receptor-binding domain (RBD)128.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
In the citing paper
“Therefore, many individuals have existing memory T cells that were generated from endemic human coronavirus infections and can cross-react with SARS-CoV-2 epitopes, known as SARS-CoV-2 cross-reactive memory T cells128.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clustal W and Clustal X version 2.0
Larkin, M., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P., McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., López, R., et al. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm404 · Cited by 28,598
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Needleman, S. B., & Wunsch, C. D. (1970) · Journal of Molecular Biology · doi:10.1016/0022-2836(70)90057-4 · Cited by 11,288
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K. W., Bleicker, T., Brünink, S., Schneider, J. A., Schmidt, M. L., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.3.2000045 · Cited by 7,266
Self-citationVirological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Self-citationWu, J. T., Leung, K., & Leung, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30260-9 · Cited by 4,389
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y., Wang, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00827 · Cited by 2,475
Cited by
Sorted by citations
Items 101–200 of 999
Guo, L., Wang, G., Wang, Y., Zhang, Q., Ren, L., Gu, X., Huang, T., Zhong, J., Wang, Y., Wang, X., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00036-2 · Cited by 174
The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
Murray, S. M., Ansari, M. A., Frater, J., Klenerman, P., Dunachie, S. J., Barnes, E. J., & Ogbe, A. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00809-x · Cited by 173
Sokołowska, M., Łukasik, Z. M., Agache, I. O., Akdiş, C. A., Akdiş, D., Akdiş, M., Barcik, W., Brough, H. A., Eiwegger, T., Eljaszewicz, A., et al. (2020) · Allergy · doi:10.1111/all.14462 · Cited by 170
Budnick, A., Hering, C., Eggert, S., Teubner, C., Suhr, R., Kuhlmey, A., & Gellert, P. R. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06359-7 · Cited by 169
Humoral signatures of protective and pathological SARS-CoV-2 infection in children
Bartsch, Y. C., Wang, C., Zohar, T., Fischinger, S., Atyeo, C. G., Burke, J. S., Kang, J., Edlow, A. G., Fasano, A., Baden, L. R., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01263-3 · Cited by 163
The known unknowns of T cell immunity to COVID-19
Karlsson, A. C., Humbert, M., & Buggert, M. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe8063 · Cited by 165
Peripheral and lung resident memory T cell responses against SARS-CoV-2
Grau-Expósito, J., Sánchez-Gaona, N., Massana, N., Suppi, M., Astorga-Gamaza, A., Perea, D., Rosado, J., Falcó-Roget, A., Kirkegaard-Biosca, C., Torrella, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23333-3 · Cited by 169
Bilich, T., Nelde, A., Heitmann, J. S., Maringer, Y., Roerden, M., Bauer, J., Rieth, J., Wacker, M., Peter, A., Hörber, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf7517 · Cited by 150
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates
Liang, J. G., Su, D., Song, T., Zeng, Y., Huang, W., Wu, J., Xu, R., Luo, P., Yang, X., Zhang, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21634-1 · Cited by 153
Rivas, M. N., Ebinger, J. E., Wu, M., Sun, N., Braun, J. G., Sobhani, K., Eyk, J. E. V., Cheng, S. C., & Arditi, M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci145157 · Cited by 152
Self-citationAdaptive Immune Responses and Immunity to SARS-CoV-2
Primorac, D., Vrdoljak, K., Brlek, P., Pavelić, E., Molnar, V., Matišić, V., Ivkošić, I. E., & Parčina, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.848582 · Cited by 162
Tortorella, C., Aiello, A., Gasperini, C., Agrati, C., Castilletti, C., Ruggieri, S., Meschi, S., Matusali, G., Colavita, F., Farroni, C., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000013108 · Cited by 156
Impaired ketogenesis ties metabolism to T cell dysfunction in COVID-19
Karagiannis, F., Peukert, K., Surace, L., Michla, M., Nikolka, F., Fox, M., Weiss, P., Feuerborn, C., Maier, P., Schulz, S., et al. (2022) · Nature · doi:10.1038/s41586-022-05128-8 · Cited by 152
Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection
Adamo, S., Michler, J., Zurbuchen, Y., Cervia, C., Taeschler, P., Raeber, M. E., Sain, S. B., Nilsson, J., Moor, A. E., & Boyman, O. (2021) · Nature · doi:10.1038/s41586-021-04280-x · Cited by 146
Evolutionary trajectory of SARS-CoV-2 and emerging variants
Singh, J., Pandit, P., McArthur, A. G., Banerjee, A., & Mossman, K. L. (2021) · Virology Journal · doi:10.1186/s12985-021-01633-w · Cited by 150
Graham, S. P., McLean, R. K., Spencer, A. J., Belij‐Rammerstorfer, S., Wright, D., Ulaszewska, M., Edwards, J. C., Hayes, J. W. P., Martini, V., Thakur, N., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-00221-3 · Cited by 138
Minervina, A. A., Komech, E. A., Titov, A., Koraichi, M. B., Rosati, E., Mamedov, I. Z., Franke, A., Efimov, G. A., Chudakov, D. M., Mora, T., et al. (2021) · eLife · doi:10.7554/elife.63502 · Cited by 147
How to interpret and use COVID-19 serology and immunology tests
Ong, D. S. Y., Fragkou, P. C., Schweitzer, V. A., Chemaly, R. F., Moschopoulos, C. D., & Skevaki, C. L. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.001 · Cited by 144
Persistent cellular immunity to SARS-CoV-2 infection
Breton, G., Mendoza, P., Hägglöf, T., Oliveira, T. Y., Schaefer-Babajew, D., Gaebler, C., Turroja, M., Hurley, A., Caskey, M., & Nussenzweig, M. C. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202515 · Cited by 129
Asthma-associated risk for COVID-19 development
Skevaki, C. L., Васильевна, К. А., Karaulov, A. V., Xie, M., & Renz, H. E. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.09.017 · Cited by 139
Impact of COVID-19 in solid organ transplant recipients
Danziger‐Isakov, L. A., Blumberg, E. A., Manuel, O., & Sester, M. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16449 · Cited by 139
Reappearance of effector T cells is associated with recovery from COVID-19
Odak, I., Barros‐Martins, J., Bošnjak, B., Stahl, K., David, S., Wiesner, O., Busch, M., Hoeper, M. M., Pink, I., Welte, T., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102885 · Cited by 139
Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2
Low, J. S., Vaqueirinho, D., Mele, F., Foglierini, M., Jerak, J., Perotti, M., Jarrossay, D., Jovic, S., Perez, L. H., Cacciatore, R., et al. (2021) · Science · doi:10.1126/science.abg8985 · Cited by 131
Divergent SARS‐CoV‐2‐specific T‐ and B‐cell responses in severe but not mild COVID‐19 patients
Oja, A. E., Saris, A., Ghandour, C. A., Kragten, N. A. M., Hogema, B. M., Nossent, E. J., Heunks, L. M. A., Cuvalay, S., Slot, E., Linty, F., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.202048908 · Cited by 145
Wei, Y., & Shah, R. (2020) · Pharmaceuticals · doi:10.3390/ph13070155 · Cited by 140
The immuno-oncological challenge of COVID-19
Derosa, L., Melenotte, C., Griscelli, F., Gachot, B., Marabelle, A., Kroemer, G., & Zitvogel, L. (2020) · Nature Cancer · doi:10.1038/s43018-020-00122-3 · Cited by 136
SARS-CoV-2 in immunocompromised individuals
DeWolf, S., Laracy, J. C., Perales, M., Kamboj, M., van den Brink, M. R. M., & Vardhana, S. A. (2022) · Immunity · doi:10.1016/j.immuni.2022.09.006 · Cited by 143
Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection
Wang, Z., Yang, X., Zhong, J., Zhou, Y., Tang, Z., Zhou, H., He, J., Mei, X., Tang, Y., Lin, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22036-z · Cited by 131
Oved, K., Olmer, L., Shemer-Avni, Y., Wolf, T., Supino-Rosin, L., Prajgrod, G., Shenhar, Y., Payorsky, I., Cohen, Y., Kohn, Y., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100651 · Cited by 129
Ogbe, A., Kronsteiner, B., Skelly, D., Pace, M. J., Brown, A., Adland, E., Adair, K., Akhter, H. D., Ali, M., Ali, S.-E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21856-3 · Cited by 124
Keller, M. D., Harris, K. M., Jensen-Wachspress, M. A., Kankate, V. V., Lang, H., Lazarski, C. A., Durkee-Shock, J. R., Lee, P., Chaudhry, K., Webber, K., et al. (2020) · Blood · doi:10.1182/blood.2020008488 · Cited by 126
T cell immunobiology and cytokine storm of COVID‐19
Luo, X., Zhu, Y., Mao, J., & Du, R. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12989 · Cited by 127
Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures
Eroshenko, N., Gill, T., Keaveney, M. K., Church, G. M., Trevejo, J., & Rajaniemi, H. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0577-1 · Cited by 122
Murugesan, K., Jagannathan, P., Pham, T. D., Pandey, S., Bonilla, H. F., Jacobson, K. B., Parsonnet, J., Andrews, J. R., Weiskopf, D., Sette, A., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1537 · Cited by 128
Gangaev, A., Ketelaars, S. L. C., Isaeva, O. I., Patiwael, S., Dopler, A., Hoefakker, K., De Biasi, S., Gibellini, L., Mussini, C., Guaraldi, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22811-y · Cited by 111
Butler, S. E., Crowley, A. R., Natarajan, H., Xu, S., Weiner, J. A., Bobak, C. A., Mattox, D. E., Lee, J., Wieland‐Alter, W., Connor, R. I., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.618685 · Cited by 120
Schwarzkopf, S., Krawczyk, A., Knop, D., Klump, H., Heinold, A., Heinemann, F. M., Thümmler, L., Temme, C., Breyer, M., Witzke, O., et al. (2020) · Emerging infectious diseases · doi:10.3201/2701.203772 · Cited by 138
Gfeller, D., Schmidt, J., Croce, G., Guillaume, P., Bobisse, S., Genolet, R., Queiroz, L., Cesbron, J., Racle, J., & Harari, A. (2023) · Cell Systems · doi:10.1016/j.cels.2022.12.002 · Cited by 128
Disease diagnostics using machine learning of B cell and T cell receptor sequences
Zaslavsky, M., Craig, E., Michuda, J., Sehgal, N., Ram-Mohan, N., Lee, J.-Y., Nguyen, K. D., Hoh, R. A., Pham, T. D., Röltgen, K., et al. (2025) · Science · doi:10.1126/science.adp2407 · Cited by 132
Schub, D., Klemis, V., Schneitler, S., Mihm, J., Lepper, P. M., Wilkens, H., Bals, R., Eichler, H., Gärtner, B. C., Becker, S. L., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.142167 · Cited by 115
Alquisiras-Burgos, I., Peralta-Arrieta, I., Alonso-Palomares, L. A., Zacapala-Gómez, A. E., Salmerón-Bárcenas, E. G., & Aguilera, P. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02134-7 · Cited by 115
Bošnjak, B., Stein, S. C., Willenzon, S., Cordes, A. K., Puppe, W., Bernhardt, G., Ravens, I., Ritter, C., Schultze-Florey, C. R., Gödecke, N., et al. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00573-9 · Cited by 115
Shah, P., Canziani, G., Carter, E. P., & CHAIKEN, I. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637651 · Cited by 111
Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
Mengist, H. M., Kombe, A. J. K., Mekonnen, D. S., Abebaw, A., Getachew, M., & Jin, T. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101533 · Cited by 115
Single-cell immunology of SARS-CoV-2 infection
Tian, Y., Carpp, L. N., Miller, H. E. R., Zager, M. A., Newell, E. W., & Gottardo, R. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01131-y · Cited by 114
SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic
Bertoletti, A., Bert, N. L., & Tan, A. T. (2022) · Immunity · doi:10.1016/j.immuni.2022.08.008 · Cited by 118
Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunity
Liu, G., Zhu, M., Zhao, X., & Nie, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113889 · Cited by 114
SARS-CoV-2 Vaccine Development: Current Status
Poland, G. A., Ovsyannikova, I. G., Crooke, S. N., & Kennedy, R. B. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.07.021 · Cited by 119
Association between HLA gene polymorphisms and mortality of COVID‐19: An in silico analysis
Tomita, Y., Ikeda, T., Sato, R., & Sakagami, T. (2020) · Immunity Inflammation and Disease · doi:10.1002/iid3.358 · Cited by 110
T cell immunity to SARS-CoV-2 following natural infection and vaccination
DiPiazza, A. T., Graham, B. S., & Ruckwardt, T. J. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.060 · Cited by 109
Keeton, R., Richardson, S. I., Moyo-Gwete, T., Hermanus, T., Tincho, M. B., Benede, N., Manamela, N. P., Baguma, R., Makhado, Z., Ngomti, A., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.10.003 · Cited by 109
Dobaño, C., Santano, R., Jiménez, A., Vidal, M., Chi, J., Melero, N. R., Popovic, M., López-Aladid, R., Fernández‐Barat, L., Tortajada, M., et al. (2021) · Translational research · doi:10.1016/j.trsl.2021.02.006 · Cited by 110
Human Coronary Plaque T Cells Are Clonal and Cross-React to Virus and Self
Chowdhury, R. R., D’Addabbo, J., Huang, X., Veizades, S. A., Sasagawa, K., Louis, D. M., Cheng, P. P., Sokol, J., Jensen, A., Tso, A., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.320090 · Cited by 106
Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors
Zsichla, L., & Müller, V. (2023) · Viruses · doi:10.3390/v15010175 · Cited by 121
Jordan, S. C. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13582 · Cited by 113
Aziz, N. A., Corman, V. M., Echterhoff, A. K. C., Müller, M. A., Richter, A. M., Schmandke, A., Schmidt, M. L., Schmidt, T. H., de Vries, F. M., Drosten, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22351-5 · Cited by 107
Self-citationCOVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications
Yamamoto, V., Bolanos, J. F., Fiallos, J., Strand, S. E., Morris, K., Shahrokhinia, S., Cushing, T. R., Hopp, L., Tiwari, A., Hariri, R., et al. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200831 · Cited by 100
Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome
Crooke, S. N., Ovsyannikova, I. G., Kennedy, R. B., & Poland, G. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-70864-8 · Cited by 104
Steinman, J. B., Lum, F., Ho, P. P.-K., Kaminski, N., & Steinman, L. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012358117 · Cited by 102
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV
Alrubayyi, A., Gea‐Mallorquí, E., Touizer, E., Hameiri‐Bowen, D., Kopycinski, J. T., Charlton, B. G., Fisher-Pearson, N., Muir, L., Rosa, A., Roustan, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26137-7 · Cited by 107
Miles, D. K., Stedman, M., & Heald, A. H. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13674 · Cited by 97
Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19
Neidleman, J. A., Luo, X., George, A. F., McGregor, M. M., Yang, J., Yun, C., Murray, V., Gill, G., Greene, W. C., Vasquez, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109414 · Cited by 97
Intra-host evolution during SARS-CoV-2 prolonged infection
Voloch, C. M., Francisco, R. D. S., de Almeida, L. G. P., Brustolini, O. J. B., Cardoso, C. C., Gerber, A. L., Guimarães, A. P. D. C., Leitão, I. D. C., Mariani, D., Ota, V. A., et al. (2021) · Virus Evolution · doi:10.1093/ve/veab078 · Cited by 99
Anticipating the long-term cardiovascular effects of COVID-19
Becker, R. C. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02266-6 · Cited by 100
Dobaño, C., Vidal, M., Santano, R., Jiménez, A., Chi, J., Barrios, D., Ruiz‐Olalla, G., Melero, N. R., Carolis, C., Parras, D., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01731-20 · Cited by 103
The immunology of SARS-CoV-2 infections and vaccines
Grigoryan, L., & Pulendran, B. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101422 · Cited by 102
Schwarzkopf, S., Krawczyk, A., Knop, D., Klump, H., Heinold, A., Heinemann, F., Thümmler, L., Temme, C., Breyer, M., Witzke, O., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2701.203772 · Cited by 141
Chen, Y., Yin, S., Tong, X., Tao, Y., Ni, J., Pan, J., Li, M., Wan, Y., Mao, M., Xiong, Y., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.006 · Cited by 98
Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2
An, X., Martinez-Paniagua, M. A., Rezvan, A., Sefat, S. R., Fathi, M., Singh, S., Biswas, S., Pourpak, M., Yee, C., Liu, X., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103037 · Cited by 98
DiPiazza, A. T., Leist, S. R., Abiona, O. M., Moliva, J. I., Werner, A. P., Minai, M., Nagata, B. M., Bock, K. W., Phung, E., Schäfer, A., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.06.018 · Cited by 92
Mechanistic Modeling of SARS‐CoV‐2 and Other Infectious Diseases and the Effects of Therapeutics
Perelson, A. S., & Ke, R. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2160 · Cited by 95
Secchi, M., Bazzigaluppi, E., Brigatti, C., Marzinotto, I., Tresoldi, C., Rovere, P. Q., Poli, A., Castagna, A., Scarlatti, G., Zangrillo, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci142804 · Cited by 94
Prakash, S., Srivastava, R., Coulon, P.-G. A., Dhanushkodi, N. R., Chentoufi, A. A., Tifrea, D. F., Edwards, R. A., Figueroa, C. J., Schubl, S. D., Hsieh, L. L., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2001438 · Cited by 91
Covid-19: Do many people have pre-existing immunity?
Doshi, P. (2020) · BMJ · doi:10.1136/bmj.m3563 · Cited by 95
COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!
Khuroo, M. S., Khuroo, M. S., Khuroo, M. S., Sofi, A. A., & Khuroo, N. S. (2020) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2020.06.003 · Cited by 92
Algaissi, A. A., Alfaleh, M. A., Hala, S. M., Abujamel, T. S., Alamri, S. S., Almahboub, S. A., Alluhaybi, K. A., Hobani, H. I., Alsulaiman, R. M., Alharbi, R. H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73491-5 · Cited by 93
Vaena, S., Chakraborty, P., Lee, H. G., Janneh, A. H., Kassir, M. F., Beeson, G., Hedley, Z., Yalcinkaya, A., Sofi, M. H., Li, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109076 · Cited by 92
Development of multi-epitope peptide-based vaccines against SARS-CoV-2
Lim, H. X., Lim, J., Jazayeri, S. D., Poppema, S., & Poh, C. L. (2020) · Biomedical Journal · doi:10.1016/j.bj.2020.09.005 · Cited by 91
Impaired function and delayed regeneration of dendritic cells in COVID-19
Winheim, E., Rinke, L., Lutz, K., Reischer, A., Leutbecher, A., Wolfram, L., Rausch, L., Kranich, J., Wratil, P. R., Huber, J. E., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009742 · Cited by 89
Niessl, J., Sekine, T., Lange, J., Kónya, V., Forkel, M., Marić, J., Rao, A., Mazzurana, L., Kokkinou, E., Weigel, W., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abk0894 · Cited by 94
Guo, L., Lin, S., Chen, Z., Cao, Y., He, B., & Lu, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01472-x · Cited by 90
Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases
Fung, T. S., & Liu, D. X. (2021) · Annual Review of Microbiology · doi:10.1146/annurev-micro-110520-023212 · Cited by 89
Francis, J. M., Leistritz-Edwards, D., Dunn, A., Tarr, C., Lehman, J. W., Dempsey, C., Hamel, A., Rayon-Estrada, V., Liu, G., Wang, Y., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1126/sciimmunol.abk3070 · Cited by 90
In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms
Cankat, S., Demael, M. U., & Swadling, L. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-01116-8 · Cited by 84
COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds
Moore, J. P., & Klasse, P. J. (2020) · Journal of Virology · doi:10.1128/jvi.01083-20 · Cited by 87
Why Does the Severity of COVID-19 Differ With Age?
Zimmermann, P., & Curtis, N. C. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003413 · Cited by 89
An Effective COVID-19 Vaccine Needs to Engage T Cells
Sauer, K., & Harris, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.581807 · Cited by 85
SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques
Lakshmanappa, Y. S., Elizaldi, S. R., Roh, J. W., Schmidt, B., Carroll, T. D., Weaver, K. D., Smith, J. C., Verma, A., Deere, J. D., Dutra, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20642-x · Cited by 92
Dykema, A. G., Zhang, B., Woldemeskel, B. A., Garliss, C. C., Cheung, L. S., Choudhury, D. M., Zhang, J., Aparicio, L., Bom, S., Rashid, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146922 · Cited by 85
Distinctive features of severe SARS-CoV-2 pneumonia
Budinger, G. R. S., Misharin, A. V., Ridge, K. M., Singer, B. D., & Wunderink, R. G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci149412 · Cited by 87
Varghese, P. M., Tsolaki, A. G., Yasmin, H., Shastri, A., Ferluga, J., Vatish, M., Madan, T., & Kishore, U. (2020) · Immunobiology · doi:10.1016/j.imbio.2020.152008 · Cited by 83
Discrete SARS-CoV-2 antibody titers track with functional humoral stability
Bartsch, Y. C., Fischinger, S., Siddiqui, S. M., Chen, Z., Yu, J., Gebre, M., Atyeo, C., Gorman, M. J., Zhu, A. L., Kang, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21336-8 · Cited by 82
Jiang, X.-L., Wang, G.-L., Zhao, X.-N., Yan, F.-H., Lin, Y., Kou, Z.-Q., Ji, S.-X., Zhang, X.-L., Li, C.-B., Duan, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21155-x · Cited by 77
Du, J., Wei, L., Li, G., Hua, M., Sun, Y., Wang, D., Han, K., Yan, Y., Song, C., Song, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.735125 · Cited by 83
Profound dysregulation of T cell homeostasis and function in patients with severe COVID‐19
Adamo, S., Chevrier, S., Cervia, C., Zurbuchen, Y., Raeber, M. E., Yang, L., Sivapatham, S., Jacobs, A., Baechli, E., Rudiger, A., et al. (2021) · Allergy · doi:10.1111/all.14866 · Cited by 83
Boppana, S., Qin, K., Files, J. K., Russell, R. M., Stoltz, R., Bibollet‐Ruche, F., Bansal, A., Erdmann, N. B., Hahn, B. H., & Goepfert, P. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009761 · Cited by 82
Natural killer cell‐mediated ADCC in SARS‐CoV‐2‐infected individuals and vaccine recipients
Hagemann, K., Riecken, K., Jung, J. M., Hildebrandt, H., Menzel, S., Bunders, M. J., Fehse, B., Koch‐Nolte, F., Heinrich, F., Peine, S., et al. (2022) · European Journal of Immunology · doi:10.1002/eji.202149470 · Cited by 76
Development and deployment of COVID-19 vaccines for those most vulnerable
Koff, W. C., Schenkelberg, T., Williams, T. M., Baric, R. S., McDermott, A. B., Cameron, C., Cameron, M. J., Frieman, M. B., Neumann, G., Kawaoka, Y., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1525 · Cited by 80
Ssemaganda, A., Nguyen, H. M., Nuhu, F., Jahan, N., Card, C. M., Kiazyk, S. A. K., Severini, G., Keynan, Y., Su, R., Ji, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30913-4 · Cited by 76
Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2
Woldemeskel, B. A., Kwaa, A. K., Garliss, C. C., Laeyendecker, O., Ray, S. C., & Blankson, J. N. (2020) · Journal of Clinical Investigation · doi:10.1172/jci143120 · Cited by 78
Metadata
- Authors
- Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., Baysal, E., Mangold, M., Henze, L., Lauster, R., Mall, M. A., Beyer, K., Röhmel, J., Voigt, S., Schmitz, J., Miltenyi, S., Demuth, I., Müller, M. A., Hocke, A., Witzenrath, M., Suttorp, N., Kern, F., Reimer, U., Wenschuh, H., Drosten, C., Corman, V. M., Giesecke-Thiel, C., Sander, L. E., & Thiel, A.
- Affiliations
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité – Universitätsmedizin Berlin (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Technische Universität Berlin (DE)
- Robert Koch Institute (DE)
- Miltenyi Biotec (Germany) (DE)
- Brighton and Sussex Medical School (GB)
- JPT Peptide Technologies (Germany) (DE)
- Corresponding author
- Sander, Leif Erik
- Thiel, Andreas
- ORCID
- Braun, Julian
- Loyal, Lucie
- Frentsch, Marco
- Wendisch, Daniel
- Georg, Philipp
- Kurth, Florian
- Hippenstiel, Stefan
- Dingeldey, Manuela
- Fauchere, Florent
- Baysal, Emre
- Mangold, Maike
- Henze, Larissa
- Mall, Marcus A.
- Beyer, Kirsten
- Voigt, Sebastian
- Demuth, Ilja
- Müller, Marcel A.
- Hocke, Andreas
- Witzenrath, Martin
- Suttorp, Norbert
- Kern, Florian
- Reimer, Ulf
- Drosten, Christian
- Corman, Victor M.
- Giesecke-Thiel, Claudia
- Sander, Leif Erik
- Thiel, Andreas
- Venue
- Nature
- Published
- 2020-07-29
- Volume
- 587
- Issue
- 7833
- Pages
- 270-274
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3045971896
- Cited by
- 1,310
- References
- 41
- Citations by year
- 2026: 16 · 2025: 37 · 2024: 91 · 2023: 143 · 2022: 283 · 2021: 480 · 2020: 259
- FWCI
- 38.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Sussex Research Online (University of Sussex) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft (KFO 339, SFB‐TR84)
- Bundesministerium für Bildung und Forschung
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, CD4+ T cells, spike protein, cross-reactive T cells, HCoV-229E, HCoV-OC43, C-terminal epitope, T cell immunity, COVID-19 vaccine design, healthy donors
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Adult, Aged, Aged, 80 and over, Cell Line, Cross Reactions, Female, Humans, Lymphocyte Activation, Male, Middle Aged, Pneumonia, Viral, CD4-Positive T-Lymphocytes, Coronavirus Infections, Epitopes, T-Lymphocyte, Coronavirus 229E, Human, Coronavirus OC43, Human, Pandemics, Coronavirus NL63, Human, Healthy Volunteers, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
